Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?

被引：5

作者：

Ayala-de Miguel, Carlos ^{[1
]}

Jimenez-Castro, Jeronimo ^{[1
]}

Sanchez-Vegas, Adrian ^{[1
]}

Diaz-Lopez, Sebastian ^{[1
]}

Chaves-Conde, Manuel ^{[1
]}

机构：

[1] Hosp Univ Virgen Valme, Serv Oncol Med, De Cadiz Km 548,9, Seville 41014, Spain

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2024年 / 202卷

关键词：

Colorectal cancer; Third-line; TAS-102; Bevacizumab; Anti-EGFR; Regorafenib; Fruquintinib; Trastuzumab-deruxtecan; PIPAC; INTRAPERITONEAL AEROSOL CHEMOTHERAPY; BEVACIZUMAB PLUS CHEMOTHERAPY; MISMATCH REPAIR-DEFICIENT; POSITIVE SOLID TUMORS; DRUG-ELUTING BEADS; LATER-LINE THERAPY; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; LIVER METASTASES;

D O I：

10.1016/j.critrevonc.2024.104454

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colorectal cancer remains the third most common cancer worldwide and the second cause of cancer-related death. Treatment advances and precision oncological medicine for these tumours have been stalled in comparison to those for other common tumours such as lung and breast cancer. However, the recent publication of the SUNLIGHT trial results with the trifluridine/tipiracil (TAS-102)-bevacizumab combination and the irruption of new molecular targets with guided treatments have opened new possibilities in third-line metastatic colorectal cancer management. Anti-EGFR rechallenge, anti-HER2 targeted therapies or the promising results of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC), are some of the available options that may modify what is presumably third-line colorectal treatment. Hereby, we present the evidence of the different treatment options in third-line colorectal cancer and beyond, as well as the possibilities of sequencing them.

引用

页数：16

共 128 条

[51] Cetuximab for the treatment of colorectal cancer [J].

Jonker, Derek J. ;

O'Callaghan, Chris J. ;

Karapetis, Christos S. ;

Zalcberg, John R. ;

Tu, Dongsheng ;

Au, Heather-Jane ;

Berry, Scott R. ;

Krahn, Marianne ;

Price, Timothy ;

Simes, R. John ;

Tebbutt, Niall C. ;

van Hazel, Guy ;

Wierzbicki, Rafal ;

Langer, Christiane ;

Moore, Malcolm J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2040-2048

[52] Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan [J].

Kagawa, Y. ;

Shinozaki, E. ;

Okude, R. ;

Tone, T. ;

Kunitomi, Y. ;

Nakashima, M. .

ESMO OPEN, 2023, 8 (04)

[53] Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis [J].

Kang, Byung Woog ;

Kim, Tae Won ;

Lee, Jae-Lyun ;

Ryu, Min-Hee ;

Chang, Heung Moon ;

Yu, Chang Sik ;

Kim, Jin Cheon ;

Kim, Jong Hoon ;

Kang, Yoon-Koo ;

Lee, Jung Shin .

MEDICAL ONCOLOGY, 2009, 26 (01) :32-37

[54] Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study [J].

Kawazoe, Akihito ;

Xu, Rui-Hua ;

Garcia-Alfonso, Pilar ;

Passhak, Maria ;

Teng, Hao-Wei ;

Shergill, Ardaman ;

Gumus, Mahmut ;

Qvortrup, Camilla ;

Stintzing, Sebastian ;

Towns, Kathryn ;

Kim, Tae Won ;

Shiu, Kai Keen ;

Cundom, Juan ;

Ananda, Sumitra ;

Lebedinets, Andrey ;

Fu, Rong ;

Jain, Rishi ;

Adelberg, David ;

Heinemann, Volker ;

Yoshino, Takayuki ;

Elez, Elena .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24) :2918-2927

[55] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer [J].

Kelly, Ronan J. ;

Bever, Katherine ;

Chao, Joseph ;

Ciombor, Kristen K. ;

Eng, Cathy ;

Fakih, Marwan ;

Goyal, Lipika ;

Hubbard, Joleen ;

Iyer, Renuka ;

Kemberling, Holly T. ;

Krishnamurthi, Smitha ;

Ku, Geoffrey ;

Mordecai, Mindy Mintz ;

Morris II, Van K. ;

Paulson, Andrew Scott ;

Peterson, Valerie ;

Shah, Manish A. ;

Le, Dung T. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)

[56] Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases [J].

Kennedy, Andrew ;

Cohn, Michael ;

Coldwell, Douglas M. ;

Drooz, Alain ;

Ehrenwald, Eduardo ;

Kaiser, Adeel ;

Nutting, Charles W. ;

Rose, Steven C. ;

Wang, Eric A. ;

Savin, Michael A. .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (04) :614-624

[57] Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis [J].

Kim, Sheehyun ;

Cha, Yongjun ;

Lim, Yoojoo ;

Roh, Hanseong ;

Kang, Jun-Kyu ;

Lee, Kyung-Hun ;

Kim, Min Jung ;

Park, Ji Won ;

Ryoo, Seung-Bum ;

Kim, Hwang-Phill ;

Jeong, Seung-Yong ;

Park, Kyu Joo ;

Han, Sae-Won ;

Kim, Tae-You .

INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (03) :571-583

[58] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer [J].

Kopetz, S. ;

Grothey, A. ;

Yaeger, R. ;

Van Cutsem, E. ;

Desai, J. ;

Yoshino, T. ;

Wasan, H. ;

Ciardiello, F. ;

Loupakis, F. ;

Hong, Y. S. ;

Steeghs, N. ;

Guren, T. K. ;

Arkenau, H. -T. ;

Garcia-Alfonso, P. ;

Pfeiffer, P. ;

Orlov, S. ;

Lonardi, S. ;

Elez, E. ;

Kim, T. -W. ;

Schellens, J. H. M. ;

Guo, C. ;

Krishnan, A. ;

Dekervel, J. ;

Morris, V. ;

Calvo Ferrandiz, A. ;

Tarpgaard, L. S. ;

Braun, M. ;

Gollerkeri, A. ;

Keir, C. ;

Maharry, K. ;

Pickard, M. ;

Christy-Bittel, J. ;

Anderson, L. ;

Sandor, V. ;

Tabernero, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17) :1632-1643

[59] What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) [J].

Kryh-Jensen, Charlotte G. ;

Fristrup, Claus W. ;

Ainsworth, Alan P. ;

Detlefsen, Sonke ;

Mortensen, Michael B. ;

Pfeiffer, Per ;

Tarpgaard, Line S. ;

Graversen, Martin .

PLEURA AND PERITONEUM, 2023, :147-155

[60] TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study [J].

Kuboki, Yasutoshi ;

Nishina, Tomohiro ;

Shinozaki, Eiji ;

Yamazaki, Kentaro ;

Shitara, Kohei ;

Okamoto, Wataru ;

Kajiwara, Takeshi ;

Matsumoto, Toshihiko ;

Tsushima, Takahiro ;

Mochizuki, Nobuo ;

Nomura, Shogo ;

Doi, Toshihiko ;

Sato, Akihiro ;

Ohtsu, Atsushi ;

Yoshino, Takayuki .

LANCET ONCOLOGY, 2017, 18 (09) :1172-1181

← 1 2 3 4 5 6 7 8 9 10 →